The estimated Net Worth of Dana Aftab is at least $14 Milión dollars as of 12 August 2024. Dr Aftab owns over 20,883 units of Exelixis Inc stock worth over $13,317,849 and over the last 2 years he sold EXEL stock worth over $668,456.
Dr has made over 4 trades of the Exelixis Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 20,883 units of EXEL stock worth $565,094 on 12 August 2024.
The largest trade he's ever made was exercising 95,000 units of Exelixis Inc stock on 7 August 2024 worth over $2,318,950. On average, Dr trades about 14,499 units every 38 days since 2023. As of 12 August 2024 he still owns at least 500,107 units of Exelixis Inc stock.
You can see the complete history of Dr Aftab stock trades at the bottom of the page.
Dr. Dana T. Aftab is the Exec. VP of Bus. Operations at Exelixis Inc.
Dana's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey a Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: